Plexxikon vets kick off new drug discovery outfit — with old assets and new target

Daiichi Sankyo shut down its South San Francisco subsidiary Plexxikon earlier this year. Now a new startup is looking to forge its own path — with 10 Plexxikon veterans, five assets from the now-defunct biotech and a focus around a new target.

Opna Bio, led by ex-Plexxikon CEO Gideon Bollag,...

Click to view original post